PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
- Resource Type
- Abstract
- Source
- In
Value in Health 2008 11(3):A248-A249 - Subject
POSTER PRESENTATIONS - Language
- ISSN
- 1098-3015